中南医学科学杂志2026，Vol.54Issue(1)：20-24,5.DOI:10.15972/j.cnki.43-1509/r.2026.01.004
利那洛肽联合普芦卡必利对IBS-C小鼠的肠黏膜屏障功能及肠道免疫的影响机制
The mechanism of linagliptin and prucabide to influence intestinal mucosal barrier function and intestinal immunity in IBS-C mice
摘要
Abstract
Aim To explore the mechanism of linagliptin and prucabide to influence intestinal mucosal barrier function and intestinal immunity in irritable bowel syndrome with constipation(IBS-C)mice.Methods Fifty C57BL/6 wild-type mice were randomly divided into a normal group,a model group,a linagliptin group,a pratacrolide group,and a dual-drug combination group.Before intervention,except for the normal group,all other groups were given ice water gavage to prepare IBS-C model mice.After 14 days of intervention,the quantity and moisture content of feces,gastric residual rate,and intestinal motility were measured in each group.HE staining was used to observe the morphology of colon tissues in each group;ELISA method was used to detect the levels of serum diamine oxidase(DAO),D-lactic acid(D-LA),and endotoxin(ET)in each group;qRT-PCR was used to detect the mRNA expression levels of interleukin(IL)-10,interferon(IFN-γ),IL-17,immunoglobulin(Ig)A,IgM,and IgG in colon tissue;Western blotting and qRT-PCR were used to detect the protein and mRNA expression levels of Toll-like receptor 4(TLR4),nuclear factor kap-pa-B p65(NF-κB p65)in colon tissue.Results Compared with the normal group,the model group showed a significant decrease in fecal particle count,fecal water content,and intestinal motility,while the gastric residual rate and serum DAO,D-LA,and ET levels were significantly increased(P<0.05);The mRNA expression of IFN-γ,IL-17,IgA,IgG,and the protein and mRNA of TLR4,NF-κB p65 were significantly increased,while the mRNA expression of IL-10 was decreased(P<0.05).Histopathology showed a small amount of inflammatory cell infiltration in the colon mucosa of the model group.The linagliptin group,prucabide group,and dual-drug combination group were all able to reverse the changes in the above indicators(P<0.05),and the improvement in various indicators in the dual-drug combination group was better than those in the single drug group(P<0.05),while the infiltration of colitis cells was reduced.Conclusion The combination of linagliptin and prucabide may improve intestinal mucosal barrier function and intestinal immune status in IBS-C mice by inhibiting the TLR4/NF-κB signaling pathway.关键词
利那洛肽/普芦卡必利/便秘型肠易激综合征/肠黏膜屏障功能/肠道免疫Key words
linagliptin/prucabide/IBS-C/intestinal mucosal barrier function/intestinal immunity分类
医药卫生引用本文复制引用
张婉,袁婷婷,王影..利那洛肽联合普芦卡必利对IBS-C小鼠的肠黏膜屏障功能及肠道免疫的影响机制[J].中南医学科学杂志,2026,54(1):20-24,5.基金项目
河北省医学科学研究课题计划项目(20221701) （20221701）
